Evaxion Biotech A/S announced that it is ready for recruitment for the Company's EVX-01 Phase 2b clinical trial, in which the Company, in collaboration with Merck*, intends to continue to treat patients with unresectable or metastatic melanoma. The clinical trial will be conducted globally and commence in Australia, with approximately 90 patients being enrolled. The Company has received regulatory approval from the Australian authorities for the trial and is now awaiting the first patient-first visit (FPFV) in the clinic, which is anticipated before the end of August 2022.
In the clinical trial, the Company will treat patients with unresectable or metastatic melanoma with a unique, personalized cancer medicine in combination with Merck's checkpoint inhibitor pembrolizumab (Keytruda®) (Standard of Care).